Caper Republic

Welcome Guest! To enable all features please try to register or login.
Global Octreotide Market Overview
goon2019
#1 Posted : 30 September 2019 16:32:40(UTC)
Rank: Advanced Member

Groups: Registered
Joined: 08/05/2019(UTC)
Posts: 303

Global Octreotide Market Overview



Solution: 50 mcg SC q8hr initially; titrate up to 500 mcg SC q8hr if necessary; after successful treatment with solution for 2 weeks, initiate treatment with suspension (depot injection)
Suspension (depot injection): 20 mg IM (gluteal) every 4 weeks for 3 months; titrate up or down to 10-30 mg IM every 4 weeks, depending on response; not to exceed 40 mg, as follows
Symptoms controlled: If GH < 1 ng/mL and IGF-1 normal, decrease dose to 10 mg IM intragluteally every 4 weeks; if GH < 2.5 ng/mL and IGF-1 normal, maintain dose at 20 mg IM every 4 weeks
Symptoms uncontrolled: If GH > 2.5 ng/mL or IGF-I elevated, increase dose to 30 mg IM every 4 weeks; if symptoms persist, increase to 40 mg IM
Dosing Considerations
Monitor IGF-1 levels every 2 weeks to guide titration; goal: GH levels <5 ng/mL or IGF-1 levels <1.9 units/mL (men) and <2.2 units/mL (women)
Monitor IGF-1 or GH levels every 6 months
Withdraw drug yearly for 4 weeks (solution) or 8 weeks (suspension) from patients who have undergone irradiation to assess
Carcinoid Tumor

Solution: 100-600 mcg/day SC divided q6-12hr; may titrate to 1500 mcg/day; after successful treatment with solution for 2 weeks, initiate treatment with suspension (depot injection)
Suspension (depot injection): 20 mg IM every 4 weeks for 2 months then modify dose based on response; may increase to 30mg q4wk if symptoms are inadequately controlled; decrease to 10 mg IM q4wk for trial period if initially responsive to 20 mg dose; dose >30 mg not recommended
VIPoma

Solution: 200-300 mcg/day SC divided q6-12hr; after successful treatment with solution for 2 weeks, initiate treatment with suspension (depot injection)
Suspension (depot injection): Patients must be stabilized on subcutaneous Octreotide powder for at least 2 weeks before switching to long-acting depot; upon switch, administer 20 mg IM intragluteally every 4 weeks for 2 months; continue solution for first 2 weeks; titrate suspension up or down to 10-30 mg IM every 4 weeks
Esophageal Variceal Bleeding (Off-label)

Solution: 25-100 mcg IV bolus (usual bolus dose: 50 mcg); follow by continuous IV infusion of 25-50 mcg/hr for 2-5 days; may repeat bolus in first hr if hemorrhage not controlled
Sponsor  
 
Rss Feed  Atom Feed
Users browsing this topic
Guest
Forum Jump  
You cannot post new topics in this forum.
You cannot reply to topics in this forum.
You cannot delete your posts in this forum.
You cannot edit your posts in this forum.
You cannot create polls in this forum.
You cannot vote in polls in this forum.

Website by Excelium Limited (www.excelium.co.uk)
Based on the YAFVision Theme by Jaben Cargman (Tiny Gecko)
Powered by YAF 1.9.5 RC1 | YAF © 2003-2010, Yet Another Forum.NET